Joe Springer

#1 Ranked Stock Analyst Now at Your Service

Come Join Us

[Shining Science @ShiningScience]

Humans are extraordinarily sensitive to the smell of rain, known as petrichor, primarily due to the compound geosmin.

We can detect geosmin at parts-per-trillion levels, whereas sharks typically detect blood in water at parts-per-million or parts-per-billion concentrations.
This means humans are roughly 200,000 times more sensitive to the scent of rain than sharks are to blood.

Such heightened sensitivity likely evolved because smelling rain helped early humans locate fresh water and fertile environments.

What seems like a pleasant aroma today was once a crucial survival signal.

[Joe Springer @JoeSpringer]

@ShiningScience Let's do it!!

[Cankay Koryak @CankayKoryak]

The Arc gene (Activity-regulated cytoskeleton-associated protein) and memory engram cell are both central to the neuroscience of learning and memory, and they are functionally linked.
Arc isn’t just a plasticity gene—it forms virus-like capsids that transfer mRNA between engram cells, helps tag active synapses, and enables memory updating. Precise Arc levels are essential: too much or too little disrupts memory. Dysregulation is linked to Alzheimer’s, but targeted rescue shows promise. (Ashley, 2023; Chen, 2024; Kim, 2024)

[Joe Springer @JoeSpringer]

Six Strong Trends For This Unknown Stock
https://t.co/Z1ZN2qLKGg

[Joe Springer @JoeSpringer]

My notes:

"Strategy explains how a company achieves sustainable value creation...Sustainable value creation is distinct from sustainable competitive advantage...Multiple companies in the same industry can achieve sustainable value creation...We place special emphasis on two of the forces: threat of new entrants and rivalry among existing firms....At a high level, barriers to entry are either structural or strategic. Structural advantages come from scale benefits that lead to lower costs, access to scarce resources, or regulation. Strategic barriers are the result of actions incumbents take to fend off or discourage entrance....The weapons of rivalry include pricing, service offerings, capacity changes, new products, advertising, and promotional spending....Cooperation tends to emerge when companies frequently interact with one another and therefore learn how to send and receive signals....Assets that companies cannot deploy elsewhere create a barrier to exit...Strategic positioning is about difference, and defines how a firm’s activities differ from those of the competition...The decomposition of financial results shows that while industry and management are relevant, strategy is the most important determinant of long-term value creation."

[Joe Springer @JoeSpringer]

This Resource Is The Next Gold

https://t.co/XW5faOIPSj

[PUNS @ThePunnyWorld]

You'll be OK

[Joe Springer @JoeSpringer]

@MattNachtrab Perspective couldn't figure this out for themselves?

Why would you say such a thing?

[Joe Springer @JoeSpringer]

@MattNachtrab LOL

Wait until the stock is 20X higher?

Is that what you did?

[Joe Springer @JoeSpringer]

@J55612435

[Joe Springer @JoeSpringer]

@swingtrader So sorry to hear

There is an encouraging new drug with data reading out by the end of the year

Drug is a major threat to the big players so the attacks on this little company are relentless

Terrific stories coming out of the trial $SAVA

https://t.co/FfapMk1vik

[Matt Nachtrab @MattNachtrab]

$sava simufilam patient with AD for ~8 years entered study at a 16 MMSE - Performs Sax Solo!!!

Just got an absolutely incredible update on patient number 1. He recently put on a Jazz performance with his band. He is playing saxophone. One patient that started the trial as a 17-18 was diagnosed with AD in 2016. A 16 MMSE was probably diagnosed with AD around 2016 as well... so 8 years with the disease and he can do a VERY GOOD SAX SOLO? WOW!!!

Patient 1
Refocus ~Nov 2022 - May 2024 : 16 MMSE to 20 MMSE

They said they will be sending evidence of their pill as well.

[Joe Springer @JoeSpringer]

@jani_kiviniemi Martina.

[Joe Springer @JoeSpringer]

@jani_kiviniemi That's her.

[Joe Springer @JoeSpringer]

@GabrielDirienzo Put it on Mars?

[Joe Springer @JoeSpringer]

Targeting integrins is gaining traction in Alzheimer's and dementia

Filamin A is a major gatekeeper to integrins

In its native conformation, filamin A's integrin binding site is auto-inhibited

Fix the conformation back to the native form --> stop integrin-induced Alzheimer's pathology

$SAVA

[Joe Springer @JoeSpringer]

More than two decades ago migfilin showed that binding filamin A in the same general place as simufilam is possible, and modulates cell shape

$SAVA

[Joe Springer @JoeSpringer]

Funny, you don't hear about the actin cytoskeleton hallmarks of Alzheimer's like cofilin and Hirano bodies

I wonder if it is because BP has no treatments related to the actin cytoskeleton?

Anyway, it seems properly shaped filamin A phosphorylates cofilin, deactivating it and preventing tauopathy

$SAVA

[Joe Springer @JoeSpringer]

$SAVA

It's done!!

[Joe Springer @JoeSpringer]

@JoshTradeOption Next up -- sleepier stocks!! Make sure we keep our winnings.

[Joe Springer @JoeSpringer]

Thank you again, Yale!

Hot of the presses!

Yale team already demonstrated simufilam's MOA and efficacy in mouse seizures.

Now they show same MOA restores cortical synaptic connectivity.

Ya know, like in Alzheimer's disease.

$SAVA

https://t.co/ykohXtLcI3